For anyone in Beeck searching for CJC-1295, the first thing to know is that this compound is available only through an online research supply market. What this means for Beeck researchers is that your location matters far less than your ability to evaluate vendor quality — and those evaluation tools are within reach of all serious researchers. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. The sections below cover what Beeck researchers need to know about purchasing, testing, and working with CJC-1295 for legitimate research applications.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Beeck comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
The first step for any Beeck researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — organic rankings are no guide to actual CJC-1295 quality. A COA for CJC-1295 should include: HPLC purity percentage with the actual chromatogram data, mass spectrometry data confirming the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. For Beeck researchers evaluating unfamiliar vendors: a test quantity before committing to research volumes before committing to research quantities is standard practice in the community. For Beeck researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Beeck
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade CJC-1295 without any obvious sign; always verify cold chain was maintained during shipping. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. The research literature on CJC-1295 should be read critically before designing any protocol — study designs, dosing ranges, and outcome measures vary significantly and not all findings translate directly.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
